Fritextsökning
Innehållstyper
-
A crash course in IP strategy
"Publish, publish, publish!" Sound familiar? So to meet the researcher's wishes, do you scribble a patent application with lipstick on a napkin and send it in? ...
-
Medicult disclaims Swedish offer
The Norwegian company Medicult's Board is highly sceptical to the yesterday announced Vitrolife offer.
-
Young, bright and committed to labtech
Ghazal Voghoui recently bought her first apartment and finally settled in Stockholm again. Last year, she finished her law studies and she is relieved to be bac...
-
Go ahead for leg wound study
Tripep starts a phase II-study of their wound healing joint venture project.
-
Microwave reactor for use in various synthesis applications
The Monowave 300 microwave reactor offers 850 watts of power for a variety of synthesis applications.
-
Dry blood DNA storage on a matrix
Qiagen recently presented a method of dry blood sample storage as an alternative to storage in freezers.
-
Biotage is regrouping
The Swedish company Biotage takes yet another step in streamlining efforts, by outsourcing all instrument production to contract manufacturers.
-
Fat cells' reaction differs with body weight
The fat cells of overweight people may react differently to dietary changes than in their lean peers, according to a pioneering study from the Dutch organizatio...
-
Norwegian describes scrapie gene
Intestinal lymphatic tissue is important for the absorption and spread of the scrapie prion, suggests a Norwegian researcher.
-
Teams up with leading dermatologist
Tripep has signed a letter of intent with a major Japanese specialty pharma company to bring their wound healing treatment to a big market.
-
Elekta gets ok from China
The Swedish medtech comapny Elekta has received approval from the Chinese authority State Food and Drug Administration, SFDA, to sell its linear accelerator in China.
-
”Bedragarna som brann för sina medicinföretag”
Life Science Swedens chefredaktör Samuel Lagercrantz kommenterar det nu aktuella Theranos-fallet och drar paralleller till en annan medicinskandal – som brisera...
-
SDU professor helps EU
Mette Præst Knudsen from the University of Southern Denmark, SDU, has been appointed as an expert member in an EU politics group.
-
Ny kunskap om sällsynt grundämne
Forskare från Göteborgs universitet har lyckats skapa små mängder av världens mest sällsynta grundämne.
-
Danisco strengthens its IP team
Danisco's division Genencor has appointed a new Vice President of Intellectual Property Strategy and Chief IP Counsel.
-
Enjoy Stockholm - the capital of Scandinavia
Welcome to Stockholm! Built on 14 islands, you are never far from the water in the capital of Sweden. Stockholm offers a wide range of museums, theaters, and at...
-
Lundbeck divests companies
The company sells all shares in one listed company plus divests four small private equity funds, for a three-figured million sum.
-
Acadia drug awarded
Acadia Pharmaceutical has got an award for a new treatment against Parkinson's disease.
-
New CEO to Promedvi
Sigrun Axelsson has taken on the leadership of the Lund-based medtech company.
-
EU says yes to Roche drug
EU approves a first in class therapy for treatment of patients with moderate to severe form of rheumatoid arthritis.
-
Peptider kan bli framtidens läkemedel
Tyska forskare rapporterar ett genombrott i arbetet med att göra små proteiner tillgängliga som läkemedel i pillerform.
-
Schizophrenia and bipolar disorder are relatives
Schizophrenia and bipolar disorder have the same genetic causes, according to a study from Karolinska Institutet.
-
Norwegian cancer therapy leaves phase II
New clinical results from Algeta highlights the potential of Alpharadin to treat bone metastases in major cancer indications.
-
EUR 2 million for peanut allergies
ALK Abelló has signed an agreement to invest EUR 2 million in the French biotechnology company DBV Technologies.